Easywell Biomedicals, Inc. (TPEX: 1799)
Taiwan
· Delayed Price · Currency is TWD 60.40
-2.30 (-3.67%)
Dec 20, 2024, 1:30 PM CST
Easywell Biomedicals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 483.81 | 271.63 | 178.9 | 197.28 | 267.65 | 359.96 | Upgrade
|
| Revenue Growth (YoY) | 100.39% | 51.83% | -9.32% | -26.29% | -25.64% | -14.13% | Upgrade
|
| Cost of Revenue | 204.7 | 100.91 | 102.58 | 146.85 | 183.69 | 324.5 | Upgrade
|
| Gross Profit | 279.11 | 170.72 | 76.31 | 50.43 | 83.96 | 35.46 | Upgrade
|
| Selling, General & Admin | 107.36 | 61.96 | 28.16 | 24.15 | 21.21 | 26.1 | Upgrade
|
| Research & Development | 280.48 | 271.5 | 209.41 | 238.14 | 221.61 | 225.33 | Upgrade
|
| Operating Expenses | 389.69 | 333.46 | 237.57 | 262.29 | 242.82 | 251.43 | Upgrade
|
| Operating Income | -110.58 | -162.74 | -161.26 | -211.86 | -158.86 | -215.97 | Upgrade
|
| Interest Expense | -20.26 | -19.26 | -17.25 | -16.08 | -16.07 | -18.31 | Upgrade
|
| Interest & Investment Income | 4.95 | 3.42 | 2.18 | 1.18 | 0.4 | 0.37 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.26 | 7.5 | 7.53 | -1.13 | -10.7 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.02 | 1.17 | 0.46 | 57.99 | 0.92 | -34.29 | Upgrade
|
| EBT Excluding Unusual Items | -125.13 | -169.91 | -168.34 | -169.91 | -184.31 | -268.2 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.08 | - | 0.07 | 0.01 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.03 | - | - | 0.24 | 1.49 | - | Upgrade
|
| Pretax Income | -125.1 | -169.91 | -168.28 | -169.66 | -182.82 | -268.2 | Upgrade
|
| Income Tax Expense | 0.27 | 0.26 | 0.12 | 0.85 | 2.03 | 0.66 | Upgrade
|
| Earnings From Continuing Operations | -125.37 | -170.17 | -168.39 | -170.51 | -184.85 | -268.86 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | -30.08 | Upgrade
|
| Net Income to Company | -125.37 | -170.17 | -168.39 | -170.51 | -184.85 | -298.94 | Upgrade
|
| Minority Interest in Earnings | 4.5 | 25.35 | 7.39 | 20.12 | 11.43 | 27.14 | Upgrade
|
| Net Income | -120.87 | -144.82 | -161 | -150.39 | -173.41 | -271.8 | Upgrade
|
| Net Income to Common | -120.87 | -144.82 | -161 | -150.39 | -173.41 | -271.8 | Upgrade
|
| Shares Outstanding (Basic) | 119 | 114 | 114 | 106 | 93 | 77 | Upgrade
|
| Shares Outstanding (Diluted) | 119 | 114 | 114 | 106 | 93 | 77 | Upgrade
|
| Shares Change (YoY) | 3.63% | 0.05% | 7.48% | 14.08% | 21.77% | 10.70% | Upgrade
|
| EPS (Basic) | -1.02 | -1.27 | -1.41 | -1.41 | -1.86 | -3.55 | Upgrade
|
| EPS (Diluted) | -1.02 | -1.27 | -1.41 | -1.41 | -1.86 | -3.55 | Upgrade
|
| Free Cash Flow | -165.62 | -169.17 | -60.99 | -136.02 | -174.83 | -193.07 | Upgrade
|
| Free Cash Flow Per Share | -1.40 | -1.48 | -0.53 | -1.28 | -1.87 | -2.52 | Upgrade
|
| Gross Margin | 57.69% | 62.85% | 42.66% | 25.56% | 31.37% | 9.85% | Upgrade
|
| Operating Margin | -22.86% | -59.91% | -90.14% | -107.39% | -59.35% | -60.00% | Upgrade
|
| Profit Margin | -24.98% | -53.31% | -90.00% | -76.23% | -64.79% | -75.51% | Upgrade
|
| Free Cash Flow Margin | -34.23% | -62.28% | -34.09% | -68.95% | -65.32% | -53.64% | Upgrade
|
| EBITDA | -61.24 | -121.01 | -116 | -160.42 | -96.31 | -149.13 | Upgrade
|
| EBITDA Margin | -12.66% | -44.55% | -64.84% | -81.32% | -35.98% | -41.43% | Upgrade
|
| D&A For EBITDA | 49.35 | 41.73 | 45.26 | 51.45 | 62.55 | 66.84 | Upgrade
|
| EBIT | -110.58 | -162.74 | -161.26 | -211.86 | -158.86 | -215.97 | Upgrade
|
| EBIT Margin | -22.86% | -59.91% | -90.14% | -107.39% | -59.35% | -60.00% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.